BusinessTop story
Bethlehem's OraSure grew revenue 14% in the third quarter but pushed back its break-even target
OraSure's revenue and margin grew while its operating loss shrank
| Q3 2025 | Measure | Q3 2026 |
|---|---|---|
| $27.09 million | Net revenues | $30.91 million |
| 43.5% | Gross margin | 45.2% |
| $16.1 million | Operating loss | $13.0 million |
Sources: WFMZ, markets.businessinsider.com
If you're rooting for a Bethlehem company, OraSure Technologies had a solid quarter. It reported net revenues of $30.9 million for the three months ended Sept. 30, up 14% from a year earlier. Gross margin improved to 45.2%, and the operating loss narrowed to $13 million.
The catch: WFMZ says OraSure now expects to break even on operational cash flow in the second half of 2027, later than it previously estimated. CFO Ken McGrath said the timing changed as growth opportunities shifted. Earlier this year, OraSure withdrew its FDA submission for its InteliQuick CT/NG chlamydia and gonorrhea test. It's not clear when the test will be resubmitted.
OraSure ended the quarter with $148 million in cash and no debt
- $148 million
- in cash and cash equivalents, with no debt
- $243.5 million
- market capitalization at Tuesday's share price
- $3.42
- a share late Tuesday afternoon, down about 3%
Source: WFMZ
- Uganda: OraQuick HIV self-test kits are being assembled at a new plant
- Ebola test: OraQuick Ebola 2.0 got FDA emergency use authorization this year
- DRC Ebola outbreak: more than 5,300 deaths




